Provided By GlobeNewswire
Last update: Oct 7, 2024
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present preclinical data for its proprietary Axiomerâ„¢ RNA editing technology platform and its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society, October 6-9, 2024, in Montreal, QC, Canada.
NASDAQ:PRQR (6/20/2025, 8:00:00 PM)
1.93
-0.01 (-0.52%)
Find more stocks in the Stock Screener